Search

Your search keyword '"Vergnenegre, A."' showing total 1,156 results
Start Over Author "Vergnenegre, A."
1,156 results on '"Vergnenegre, A."'

1. Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08–2015 ENERGY): a randomised, open-label, phase 3 study

Author

LENA, Hervé, VERGNENEGRE, Alain, LOCHER, Chrystèle, GEIER, Margaux, PASCAL, Thomas, GREILLIER, Laurent, FOURNEL, Pierre, PEROL, Maurice, FALCHERO, Lionel, MARTINEZ, Stéphanie, PALEIRON, Nicolas, GUISIER, Florian, LE GARFF, Gwenaëlle, DOUBRE, Hélène, HOMINAL, Stéphane, AULIAC, Jean-Bernard, WISLEZ, Marie, DE CHABOT, Gonzague, HAUSS, Pierre-Alexandre, MONNET, Isabelle, ASSOULINE, Pascal, DUJON, Cécile, LE FLOCH, Hervé, DEMONTROND, Pierre, LAMY, Régine, FRANCOIS, Géraldine, MARCQ, Marie, AUDIGIER-VALETTE, Clarisse, MADROSZYK-FLANDIN, Anne, CREQUIT, Jacky, SCHOTT, Roland, ABDICHE, Samir, SABATINI, Marielle, CHATELLIER, Thierry, CORRE, Romain, LE TREUT, Jacques, Léna, Hervé, Greillier, Laurent, Cropet, Claire, Bylicki, Olivier, Monnet, Isabelle, Audigier-Valette, Clarisse, Falchero, Lionel, Vergnenègre, Alain, Demontrond, Pierre, Geier, Margaux, Guisier, Florian, Hominal, Stéphane, Locher, Chrystèle, Corre, Romain, Chouaid, Christos, and Ricordel, Charles

Published
2024
Full Text
View/download PDF

2. Safety of immune checkpoint inhibitor rechallenge after severe immune-related adverse events: a retrospective analysis

Author

Céline Eldani, Marie Kostine, Maxime Faure, Estibaliz Lazaro, Claire Rigothier, Jean Baptiste Hiriart, Bérénice Teulières, Florian Poullenot, Magalie Haissaguerre, Maeva Zysman, Rémi Veillon, Charlotte Vergnenegre, Nahema Issa, Charlotte Domblides, Sorilla Mary-Prey, Marie Beylot-Barry, Anne Pham-Ledard, Caroline Dutriaux, Guilhem Sole, Fanny Duval, and Emilie Gerard

Subjects
immune checkpoint inhibitors (ICIs), immune related adverse events (irAEs), rechallenge, neurological immune-related adverse events, myocarditis, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Immune checkpoint inhibitors (ICIs) present clinicians with the challenge of managing immune-related adverse events (irAEs), which can range from mild to severe due to immune system activation 1. While guidelines recommend discontinuing ICIs for grade 3 partial and all grade 4 irAEs, there is growing interest in rechallenging patients based on oncological outcomes, particularly for cardiovascular and neurological irAEs where data remains scarce 1,2. We retrospectively evaluated the safety of ICI rechallenge following grade 3-4 irAEs, specifically focusing on cardiovascular and neurological events, in patients discussed at our multidisciplinary immunotoxicity assessment board between 2019 and 2021. Fifteen patients were included, with a median time to severe irAE onset of 49 days. Among them, five patients experienced neurological adverse events (NAEs): aseptic meningitis (3), inflammatory polyradiculoneuropathy (1), and ophthalmoplegia (1), while one patient presented with myocarditis. Of the 15 patients retreated with ICIs after initial severe irAEs, 11 (73%) remained free of subsequent irAEs, two (13%) experienced recurrence of the initial irAE, and two (13%) developed new irAEs distinct from the initial event. The median time to event recurrence was 69 days, occurring no earlier than the initial severe irAE. In the subset analysis focusing on severe cardiovascular and neurological irAEs, rechallenge with ICIs was generally well tolerated. However, one patient treated with anti-PD1 experienced a relapse of grade 2 aseptic meningitis. Overall, our findings suggest that rechallenging with ICIs after severe irAEs, including those affecting the cardiovascular and neurological systems, may be safe, particularly after irAE regression and corticosteroid withdrawal.

Published
2024
Full Text
View/download PDF

4. A prospective analysis of the management practices for patients with Stage-III-N2Non-Small-Cell lung cancer (OBSERVE IIIA–B GFPC 04-2020Study)

Author

Jacob, Mathilde, Fournel, Pierre, Tissot, Claire, Cadranel, Jacques, Bylicki, Olivier, Monnet, Isabelle, Justeau, Grégoire, Ricordel, Charles, Thomas, Pascal, Falchero, Lionel, Locher, Chrystel, Wislez, Marie, Vergnenegre, Alain, Abdiche, Samir, Guisier, Floran, Bizieux, Acya, Lamy, Regine, François, Geraldine, De Chabot, Gonzagues, Pierret, Thomas, Sabatini, Marie, Abeillera, Marion, Vieillot, Sabine, Martinez, Stephanie, Morel, Hugues, Doubre, Hélène, Madroszyk, Anne, Geier, Margaux, LucLabourey, Jean, Chouaïd, Christos, and Greillier, Laurent

Published
2024
Full Text
View/download PDF

5. Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06–2018 study)

Author

Amari, Lyria, Tomasini, Pascale, Dantony, Emmanuelle, Rousseau-Bussac, Gaelle, Ricordel, Charles, Bigay-Game, Laurence, Arpin, Dominique, Morel, Hugues, Veillon, Remi, Justeau, Grégoire, Huchot, Eric, Fournel, Pierre, Vergnenegre, Alain, Bizeux, Acya, Subtil, Fabien, Clarisse, Bénédicte, Decroisette, Chantal, Chouaid, Christos, Greillier, Laurent, and Bylicki, Olivier

Published
2024
Full Text
View/download PDF

6. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Author

Abdel-Karim, Isam, Abdelsalam, Mahmoud, Addeo, Alfredo, Aguado, Carlos, Alexander, Patrick, Alt, Jürgen, Azzi, Georges, Balaraman, Rama, Biesma, Bonne, Blackhall, Fiona, Bohnet, Sabine, Boleti, Ekaterini, Borghaei, Hossein, Bradbury, Penelope, Brighenti, Matteo, Campbell, Nicholas, Campbell, Toby, Canon, Jean-Luc, Cappuzzo, Federico, Costa, Enric Carcereny, Cavanna, Luigi, Cetnar, Jeremy, Chella, Antonio, Chouaid, Christos, Christoph, Daniel, Castán, Javier Cortés, Dakhil, Shaker, de Castro Carpeño, Francisco Javier, de Marinis, Filippo, Delmonte, Angelo, Demedts, Ingel, Demey, Wim, Dits, Joyce, del Pilar Diz Taín, Maria, Gómez, Manuel Dómine, Dorius, Timothy, Dumoulin, Daphne, Duruisseaux, Michaël, Eaton, Keith, González, Emilio Esteban, Evans, Devon, Faehling, Martin, Farrell, Nicholas, Feinstein, Trevor, Font, Enriqueta Felip, Garcia Campelo, Maria Rosario, Garon, Edward, Garrido López, María Pilar, Germonpré, Paul, Gersten, Todd, Cao, Maria Gonzalez, Gopaluni, Srivalli, Greillier, Laurent, Grossi, Francesco, Guisier, Florian, Gurubhagavatula, Sarada, Calderón, Vanesa Gutiérrez, Hakimian, David, Hall, Richard, Jr., Hao, Desirée, Harris, Ronald, Hashemi, Sayed, He, Kai, Hendriks, Lizza, Huang, Chao, Ibrahim, Emad, Jain, Sharad, Johnson, Melissa, Jones, Benjamin, Jones, Monte, Juan Vidal, Óscar José, Juergens, Rosalyn, Kaderbhai, Courèche, Kastelijn, Elisabeth A (Lisanne), Keresztes, Roger, Kio, Ebenezer, Kokowski, Konrad, Konduri, Kartik, Kulkarni, Swati, Kuon, Jonas, Kurkjian, Carla, Labbé, Catherine, Lerner, Rachel, Lim, Farah, Madroszyk-Flandin, Anne, Marathe, Omkar, Martincic, Danko, McClay, Edward, McIntyre, Kristi, Mekhail, Tarek, Misino, Andrea, Molinier, Olivier, Morabito, Alessandro, Morócz, Éva, Müller, Veronika, Nagy, Tünde, Nguyen, Anthony V., Nidhiry, Emmanuel, Okazaki, Ian, Ortega-Granados, Ana Laura, Ostoros, Gyula, Oubre, David, Owen, Scott, Pachipala, Krishna, Park, David, Patel, Pareshkumar, Percent, Ivor, Pérol, Maurice, Peters, Solange, Piet, Berber, Planchard, David, Polychronis, Andreas, Aix, Santiago Ponce, Pons-Tostivint, Elvire, Popat, Sanjaykumar, Pulla, Mariano Provencio, Quantin, Xavier, Quéré, Gilles, Rafique, Noman, Ramaekers, Ryan, Reck, Martin, Reiman, Anthony, Reinmuth, Niels, Reynolds, Craig, Rodríguez-Abreu, Delvys, Romano, Gianpiero, Roque, Tammy, Salzberg, Matthew, Sanborn, Rachel, Sandiego, Sergio, Schaefer, Eric, Schreeder, Marshall, Seetharamu, Nagashree, Seneviratne, Lasika, Shah, Purvi, Shunyakov, Leonid, Slater, Dennis, Parra, Hector Soto, Stigt, Johannes, Stilwill, Joseph, Su, Jingdong, Surmont, Veerle, Swink, Alicia, Szalai, Zsuzsanna, Talbot, Toby, Garcia, Alvaro Taus, Theelen, Willemijn, Thompson, Jonathan, Tiseo, Marcello, Uprety, Dipesh, Uyeki, James, van der Leest, Kornelius Cor, Van Ho, Anthony, van Putten, John, Estévez, Sergio Vázquez, Veatch, Andrea, Vergnenègre, Alain, Ward, Patrick, Weise, Amy, Weiss, Matthias, Whitehurst, Matthew, Zai, Silvia, Zalcman, Gérard, Zuniga, Richard, Borghaei, H., de Marinis, F., Dumoulin, D., Reynolds, C., Theelen, W.S.M.E., Percent, I., Gutierrez Calderon, V., Johnson, M.L., Madroszyk-Flandin, A., Garon, E.B., He, K., Planchard, D., Reck, M., Popat, S., Herbst, R.S., Leal, T.A., Shazer, R.L., Yan, X., Harrigan, R., and Peters, S.

Published
2024
Full Text
View/download PDF

7. Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer

Author

Karachaliou, Niki, Codony-Servat, Jordi, Teixidó, Cristina, Pilotto, Sara, Drozdowskyj, Ana, Codony-Servat, Carles, Giménez-Capitán, Ana, Molina-Vila, Miguel Angel, Bertrán-Alamillo, Jordi, Gervais, Radj, Massuti, Bartomeu, Morán, Teresa, Majem, Margarita, Felip, Enriqueta, Carcereny, Enric, García-Campelo, Rosario, Viteri, Santiago, González-Cao, María, Morales-Espinosa, Daniela, Verlicchi, Alberto, Crisetti, Elisabetta, Chaib, Imane, Santarpia, Mariacarmela, Luis Ramírez, José, Bosch-Barrera, Joaquim, Felipe Cardona, Andrés, de Marinis, Filippo, López-Vivanco, Guillermo, Miguel Sánchez, José, Vergnenegre, Alain, Sánchez Hernández, José Javier, Sperduti, Isabella, Bria, Emilio, and Rosell, Rafael

Published
2023
Full Text
View/download PDF

11. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

Author

Paz-Ares, Luis G., Ramalingam, Suresh S., Ciuleanu, Tudor-Eliade, Lee, Jong-Seok, Urban, Laszlo, Caro, Reyes Bernabe, Park, Keunchil, Sakai, Hiroshi, Ohe, Yuichiro, Nishio, Makoto, Audigier-Valette, Clarisse, Burgers, Jacobus A., Pluzanski, Adam, Sangha, Randeep, Gallardo, Carlos, Takeda, Masayuki, Linardou, Helena, Lupinacci, Lorena, Lee, Ki Hyeong, Caserta, Claudia, Provencio, Mariano, Carcereny, Enric, Otterson, Gregory A., Schenker, Michael, Zurawski, Bogdan, Alexandru, Aurelia, Vergnenegre, Alain, Raimbourg, Judith, Feeney, Kynan, Kim, Sang-We, Borghaei, Hossein, O'Byrne, Kenneth John, Hellmann, Matthew D., Memaj, Arteid, Nathan, Faith Ellen, Bushong, Judith, Tran, Phuong, Brahmer, Julie R., and Reck, Martin

Published
2022
Full Text
View/download PDF

12. A prospective observational study for justification, safety, and efficacy of a third dose of mRNA vaccine in patients receiving maintenance hemodialysis

Author

François, Chantrel, Mathilde, Reydit, Aurélien, Tiple, Clémence, Bechade, Abdelkader, Bemrah, Cécile, Vigneau, Bénédicte, Sautenent, Isabelle, Kazes, Cécile, Courivaud, Jean-Marc, Gabriel, Stéphane, Edet, Lucile, Mercadal, Olivier, Moranne, Fatouma, Toure, Emmanuelle, Laurain, Alex, Ranlin, Nathalie, Longlune, François, Glowacki, Jean-Michel, Tivollier, Philippe, Brunet, Fréderic, Lavainne, Etienne, Berard, Ayman, Sarraj, Marc, Bauwens, Pascale, Testevuide, Henri, Vacher Coponat, Roula, Galland, Nicole, Schauder, Louis -Rachid, Salmi, Damiano, Cerasuolo, Anaïs, Tendron-Franzin, Sahar, Bayat, Michel, Halimi Jean, Aurore, Wolak, Stéphanie, Gentile, Bénédicte, Devictor, Elisabeth, Monnet, Denis, Boucaut Maitre, Mathieu, Nacher, Véronique, Merle, Jean-Philippe, Jais, Jean-Pierre, Daures, Alain, Vergnenegre, Carole, Loos-Ayav, Sylvie, Merle, Marc, Hazzan, Shirley, Gervolino, Jean-Michel, Nguyen, Silvia, Iacobelli, Espi, Maxime, Charmetant, Xavier, Barba, Thomas, Mathieu, Cyrille, Pelletier, Caroline, Koppe, Laetitia, Chalencon, Elodie, Kalbacher, Emilie, Mathias, Virginie, Ovize, Anne, Cart-Tanneur, Emmanuelle, Bouz, Christine, Pellegrina, Laurence, Morelon, Emmanuel, Juillard, Laurent, Fouque, Denis, Couchoud, Cécile, and Thaunat, Olivier

Published
2022
Full Text
View/download PDF

13. Clinical management of molecular alterations identified by high throughput sequencing in patients with advanced solid tumors in treatment failure: Real-world data from a French hospital

Author

Sandra Pinet, Stéphanie Durand, Alexandre Perani, Léa Darnaud, Fifame Amadjikpe, Mathieu Yon, Tiffany Darbas, Alain Vergnenegre, Thomas Egenod, Yannick Simonneau, Valérie Le Brun-Ly, Julia Pestre, Laurence Venat, Frédéric Thuillier, Alain Chaunavel, Mathilde Duchesne, Véronique Fermeaux, Anne Guyot, Sylvain Lacorre, Barbara Bessette, Fabrice Lalloué, Karine Durand, and Elise Deluche

Subjects
cancer, FoundationOne CDx, next-generation sequencing, liquid biopsy, targeted therapy, precision oncology, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

BackgroundIn the context of personalized medicine, screening patients to identify targetable molecular alterations is essential for therapeutic decisions such as inclusion in clinical trials, early access to therapies, or compassionate treatment. The objective of this study was to determine the real-world impact of routine incorporation of FoundationOne analysis in cancers with a poor prognosis and limited treatment options, or in those progressing after at least one course of standard therapy.MethodsA FoundationOneCDx panel for solid tumor or liquid biopsy samples was offered to 204 eligible patients.ResultsSamples from 150 patients were processed for genomic testing, with a data acquisition success rate of 93%. The analysis identified 2419 gene alterations, with a median of 11 alterations per tumor (range, 0–86). The most common or likely pathogenic variants were on TP53, TERT, PI3KCA, CDKN2A/B, KRAS, CCDN1, FGF19, FGF3, and SMAD4. The median tumor mutation burden was three mutations/Mb (range, 0–117) in 143 patients with available data. Of 150 patients with known or likely pathogenic actionable alterations, 13 (8.6%) received matched targeted therapy. Sixty-nine patients underwent Molecular Tumor Board, which resulted in recommendations in 60 cases. Treatment with genotype-directed therapy had no impact on overall survival (13 months vs. 14 months; p = 0.95; hazard ratio = 1.04 (95% confidence interval, 0.48–2.26)].ConclusionsThis study highlights that an organized center with a Multidisciplinary Molecular Tumor Board and an NGS screening system can obtain satisfactory results comparable with those of large centers for including patients in clinical trials.

Published
2023
Full Text
View/download PDF

14. Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC

Author

Jassem, Jacek, de Marinis, Filippo, Giaccone, Giuseppe, Vergnenegre, Alain, Barrios, Carlos H., Morise, Masahiro, Felip, Enriqueta, Oprean, Cristina, Kim, Young-Chul, Andric, Zoran, Mocci, Simonetta, Enquist, Ida, Komatsubara, Kimberly, McCleland, Mark, Kuriki, Hiroshi, Villalobos, Monette, Phan, See, Spigel, David R., and Herbst, Roy S.

Published
2021
Full Text
View/download PDF

15. Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events

Author

Kostine, Marie, Mauric, Eleonora, Tison, Alice, Barnetche, Thomas, Barre, Aurélien, Nikolski, Macha, Rouxel, Léa, Dutriaux, Caroline, Dousset, Léa, Prey, Sorilla, Beylot-Barry, Marie, Seneschal, Julien, Veillon, Rémi, Vergnenegre, Charlotte, Daste, Amaury, Domblides, Charlotte, Sionneau, Baptiste, Gross-Goupil, Marine, Ravaud, Alain, Forcade, Edouard, and Schaeverbeke, Thierry

Published
2021
Full Text
View/download PDF

16. Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02–15 study)

Author

Auliac, Jean-Bernard, Monnet, Isabelle, Bizieux, Acya, Greillier, Laurent, Geier, Margaux, Falchero, Lionel, Le Garff, Gwenaelle, Lamy, Régine, Guisier, Florian, Ricordel, Charles, Chouaid, Christos, and Vergnenegre, Alain

Published
2021
Full Text
View/download PDF

19. Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer

Author

Niki Karachaliou, Jordi Codony-Servat, Cristina Teixidó, Sara Pilotto, Ana Drozdowskyj, Carles Codony-Servat, Ana Giménez-Capitán, Miguel Angel Molina-Vila, Jordi Bertrán-Alamillo, Radj Gervais, Bartomeu Massuti, Teresa Morán, Margarita Majem, Enriqueta Felip, Enric Carcereny, Rosario García-Campelo, Santiago Viteri, María González-Cao, Daniela Morales-Espinosa, Alberto Verlicchi, Elisabetta Crisetti, Imane Chaib, Mariacarmela Santarpia, José Luis Ramírez, Joaquim Bosch-Barrera, Andrés Felipe Cardona, Filippo de Marinis, Guillermo López-Vivanco, José Miguel Sánchez, Alain Vergnenegre, José Javier Sánchez Hernández, Isabella Sperduti, Emilio Bria, and Rafael Rosell

Subjects
Medicine, Science
Published
2023
Full Text
View/download PDF

20. Safety of immune checkpoint inhibitor rechallenge after severe immune-related adverse events: a retrospective analysis.

Author

Eldani, Céline, Kostine, Marie, Faure, Maxime, Lazaro, Estibaliz, Rigothier, Claire, Hiriart, Jean Baptiste, Teulières, Bérénice, Poullenot, Florian, Haissaguerre, Magalie, Zysman, Maeva, Veillon, Rémi, Vergnenegre, Charlotte, Issa, Nahema, Domblides, Charlotte, Mary-Prey, Sorilla, Beylot-Barry, Marie, Pham-Ledard, Anne, Dutriaux, Caroline, Sole, Guilhem, and Duval, Fanny

Subjects
DRUG side effects, IMMUNE checkpoint inhibitors, RETROSPECTIVE studies, CARDIOVASCULAR system, CANCER patients
Abstract

Immune checkpoint inhibitors (ICIs) present clinicians with the challenge of managing immune-related adverse events (irAEs), which can range from mild to severe due to immune system activation. While guidelines recommend discontinuing ICIs for grade 3 partial and all grade 4 irAEs, there is growing interest in rechallenging patients based on oncological outcomes, particularly for cardiovascular and neurological irAEs where data remains scarce. We retrospectively evaluated the safety of ICI rechallenge following grade 3-4 irAEs, specifically focusing on cardiovascular and neurological events, in patients discussed at our multidisciplinary immunotoxicity assessment board between 2019 and 2021. Fifteen patients were included, with a median time to severe irAE onset of 49 days. Among them, five patients experienced neurological adverse events (NAEs): aseptic meningitis (3), inflammatory polyradiculoneuropathy (1), and ophthalmoplegia (1), while one patient presented with myocarditis. Of the 15 patients retreated with ICIs after initial severe irAEs, 11 (73%) remained free of subsequent irAEs, two (13%) experienced recurrence of the initial irAE, and two (13%) developed new irAEs distinct from the initial event. The median time to event recurrence was 69 days, occurring no earlier than the initial severe irAE. In the subset analysis focusing on severe cardiovascular and neurological irAEs, rechallenge with ICIs was generally well tolerated. However, one patient treated with anti-PD1 experienced a relapse of grade 2 aseptic meningitis. Overall, our findings suggest that rechallenging with ICIs after severe irAEs, including those affecting the cardiovascular and neurological systems, may be safe, particularly after irAE regression and corticosteroid withdrawal. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Assessment of preoperative noninvasive ventilation before lung cancer surgery: The preOVNI randomized controlled study

Author

Couturaud, Francis, Gut-Gobert, Christophe, Barnier, Aude, Noël-Savina, Elise, Bazire, Amélie, Payet, Annabelle, Paleiron, Nicolas, Berard, Henri, Andre, Michel, Grassin, Frédéric, Margery, Jacques, Vaylet, Fabien, Vinas, Florent, Chouaïd, Christos, Venissac, Nicolas, Donzel-Raynaud, Christine, Lancelin, Christophe, RAUT, Yvonnick, Salley, Nicolas, Corre, Romain, Kerjouan, Mallorie, Cuvelier, Antoine, Gounane, Cherifa, Blandin, Sonia, Falchero, Lionel, Le Treut, Jacques, Aze, Olivier, Gagnadoux, Frédéric, Trzepizur, Wojciech, Vergnenegre, Alain, Egenod, Thomas, Tiffet, Olivier, Parietti, Eric, Tromeur, Cécile, and Natale, Claudia

Published
2020
Full Text
View/download PDF

22. Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial

Author

Baize, Nathalie, Monnet, Isabelle, Greillier, Laurent, Geier, Margaux, Lena, Hervé, Janicot, Henri, Vergnenegre, Alain, Crequit, Jacky, Lamy, Regine, Auliac, Jean-Bernard, Letreut, Jacques, Le Caer, Hervé, Gervais, Radj, Dansin, Eric, Madroszyk, Anne, Renault, Patrick-Aldo, Le Garff, Gwenaëlle, Falchero, Lionel, Berard, Henri, Schott, Roland, Saulnier, Patrick, and Chouaid, Christos

Published
2020
Full Text
View/download PDF

24. Management and outcomes of non–small cell lung cancer patients with rapid progression under second‐or‐more‐line immune checkpoint inhibitors: ERORECI study (GFPC 2016‐04)

Author

Alain Vergnenegre, Margaux Geier, Florian Guisier, Regine Lamy, Bénédicte Comet, Gwenaelle Le Garff, Pascal Do, Henri Janicot, Hugues Morel, Chantal Decroisette, Michel Andre, Lionel Falchero, Nicolas Paleiron, Isabelle Monnet, and the GFPC Team

Subjects
immune checkpoint inhibitors, non–small cell lung cancer, rapid progression, second‐line treatment, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Immune checkpoint inhibitors (ICIs) have been approved as second‐line therapy for advanced non–small cell lung cancers (NSCLCs) progressing after platinum‐based chemotherapy. However, some patients' disease progressed rapidly and sometimes exhibited explosive tumor progression. This descriptive, prospective study aimed to assess the characteristics of nonresponders with rapid progression (RP), defined as progression‐free survival (PFS) ≤2 or 2‐4 months under ICIs. Methods This analysis included all consecutive ICI‐treated (second‐or‐more line) patients with RP ≤4 months from 1 September 2016 to 31 August 2017 and compared the clinical characteristics, treatments, and outcomes (overall survival [OS]; responses; PFS, according to treatment line) of NSCLCs that progressed after ≤2 vs 2‐4 months on ICIs. Results Comparisons of the 224 (70.2%) patients with ≤2‐month and 95 (29.8%) with 2‐ to 4‐month RP revealed the former had less frequent nonsmokers and ECOG PS = 0, more frequent stage IV disease and higher neutrophil/lymphocyte ratio. Their respective ICI PFS rates were: 1.6 [95% CI: 0.1‐2] and 2.7 [2.0‐4.2] months, with 16.5% and 11.6% having partial responses to first‐ and second‐line therapies post‐ICI chemotherapy. Their respective median OS rates were 6.0 and 9.0 months (P ≤ .009). Multivariate analysis retained only PFS of the first‐line therapy pre‐ICI and neutrophil/lymphocyte ratio at ICI onset as being significantly associated with ≤2‐month RP. Conclusion In the real‐life setting, NSCLC RP on ICI remains a challenge. New descriptive and analytic studies are needed to identify factors predictive of RP.

Published
2020
Full Text
View/download PDF

31. Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC – IFCT 02-01

Author

Fournel, P., Talabard, J.N., Vergnenégre, A., Melloni, B., Decroisette, C., Clavére, P., Robinet, G., Bayle, S., Labat, J.P., Léna, H., Belleguic, C., Benchalal, M., Gervais, R., Rivière, A., Lerouge, D., Souquet, P.J., Gérinière, L., D'Hombres, A., Mornex, F., Le Caer, H., Tessier, E., Ramos, H., Chavaillon, J.M., Chouaid, C., Touboul, E., Bota, S., Thiberville, L., Gallocher, O., Quoix, E., Mennecier, B., Jung, G.M., Falchero, L., Paillotin, D., Schouabe, S., Jonveaux, E., Bout, J.C., Martin, P., Perol, M., Arpin, D., Martel-Lafay, I., Letreut, J., Poirier, R., Benyoub, A., Vernejoux, J.M., Trouette, R., Dansin, E., Berard, H., Pietra, J.C., Zalcman, G., Thomas, P., Zribi, A., Milleron, B., Lavolé, A., Coetmeur, D., Lamezec, B., Bonnamour, C., Grangeon, V., Suchaud, J.P., Créquit, J., Ramdane, S., Barre, P., Zawadi, M.A., Gimenez, C., Barlesi, F., Pignon, T., Grivaux, M., Blanchon, F., Mandet, J., Perdu, D., Cauchois, A., Delhoume, J.Y., Kin, B., Merle, P., Janicot, H., Verrelle, P., Auliac, J.B., Coscas, Y., Ducolone, A., Herman, D., Roquette, A., Fournel, Pierre, Vergnenégre, Alain, Robinet, Gilles, Léna, Hervé, Gervais, Radj, Le Caer, Hervé, Souquet, Pierre-Jean, Chavaillon, Jean-Michel, Bozonnat, Marie-Cécile, Daurès, Jean-Pierre, Chouaid, Christos, and Martel-Lafay, Isabelle

Published
2016
Full Text
View/download PDF

32. Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo)

Author

Alain Vergnenegre, Isabelle Monnet, Charles Ricordel, Acya Bizieux, Hubert Curcio, Marie Bernardi, Romain Corre, Florian Guisier, Stéphane Hominal, Gwenaelle Le Garff, Olivier Bylicki, Chrystèle Locher, Margaux Geier, Christos Chouaïd, and Gilles Robinet

Subjects
Pulmonary and Respiratory Medicine, Cancer Research, Oncology
Published
2023
Full Text
View/download PDF

38. Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies

Author

Moran, T., Wei, J., Cobo, M., Qian, X., Domine, M., Zou, Z., Bover, I., Wang, L., Provencio, M., Yu, L., Chaib, I., You, C., Massuti, B., Song, Y., Vergnenegre, A., Lu, H., Lopez-Vivanco, G., Hu, W., Robinet, G., Yan, J., Insa, A., Xu, X., Majem, M., Chen, X., de las Peñas, R., Karachaliou, N., Sala, M.A., Wu, Q., Isla, D., Zhou, Y., Baize, N., Zhang, F., Garde, J., Germonpre, P., Rauh, S., ALHusaini, H., Sanchez-Ronco, M., Drozdowskyj, A., Sanchez, J.J., Camps, C., Liu, B., Rosell, R., Colinet, B., De Grève, J., Germonpré, P., Chen, H., Du, J., Gao, Y., Hu, J., Kong, W., Li, L., Li, R., Li, X., Liu, J., Ren, W., Wen, L., Xiao, X., Yang, J., Yang, M., Yang, Y., Yin, J., Yue, X., Zhang, J., Zhu, L., Bombaron, P., Chouaid, C., Dansin, E., Fournel, P., Fraboulet, G., Gervais, R., Hominal, S., Kahlout, S., Lecaer, H., Lena, H., LeTreut, J., Locher, C., Molinier, O., Monnet, I., Oliviero, G., Schoot, R., Thomas, P., Vergnènegre, A., Berchem, G., Al Husaini, H., Aparisi, F., Arriola, E., Ballesteros, I., Barneto, I., Bernabé, R., Blasco, A., Bosch-Barrera, J., Calvo de Juan, V., Carcereny, E., Catot, S., De las Peñas, R., Dómine, M., Felip, E., García-Campelo, M.R., García-Girón, C., García-Gómez, R., Garcia-Sevila, R., Gasco, A., Gil, J., González-Larriba, J.L., Hernando-Polo, S., Jantus, E., Jiménez, B., Lianes, P., López-López, R., López-Martín, A., López-Vivanco, G., Macias, J.A., Marti-Ciriquian, J.L., Montoyo, R., Morales-Espinosa, D., Morán, T., Moreno, M.A., Pallares, C., Parera, M., Pérez-Carrión, R., Porta, R., Reguart, N., Rosillo, F., Sanchez, J.M., Sullivan, I., Terrasa, J., Trigo, J.M., Valdivia, J., Viñolas, N., Viteri, S., Botia-Castillo, M., Mate, J.L., Perez-Cano, M., Ramirez, J.L., Sanchez-Rodriguez, B., Taron, M., Tierno-Garcia, M., Mijangos, E., Ocaña, J., Pereira, E., Shao, J., Sun, X., and O'Brate, R.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results